{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:50:58Z","timestamp":1791283858498,"version":"4.1.0"},"reference-count":19,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,11,7]],"date-time":"2017-11-07T00:00:00Z","timestamp":1510012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2017,11,7]],"date-time":"2017-11-07T00:00:00Z","timestamp":1510012800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hyperhidrosis is a common medical condition which can have a significant impact on quality of life. Umeclidinium (UMEC) is a long\u2010acting muscarinic antagonist (LAMA) developed as a dermal formulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This 2\u2010week, double\u2010blind, randomized, vehicle\u2010controlled study evaluated systemic exposure, safety and tolerability of topically administered UMEC in subjects with primary axillary hyperhidrosis. Clinical effect was a secondary objective, measured by gravimetry and the hyperhidrosis disease severity scale (HDSS). Vehicle was included to evaluate safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Twenty\u2010three subjects were randomized to either 1.85% UMEC (\n                      <jats:italic>N<\/jats:italic>\n                      = 18) or vehicle (\n                      <jats:italic>N<\/jats:italic>\n                      = 5) once daily.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Measurable plasma concentrations were observed in 78% of subjects after the treatment. Nine subjects (50%) on UMEC and two subjects (40%) on vehicle reported AEs, most commonly application site reactions. At Day 15, seven subjects (41%) in UMEC and two subjects (40%) in vehicle had at least a 50% reduction in sweat production. Eight subjects (47%) in UMEC and one subject (20%) in vehicle had at least a two\u2010point reduction in HDSS. No comparisons of treatment arms were planned prospectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The measurable exposure, acceptable safety and preliminary clinical activity observed in this proof\u2010of\u2010concept study suggest the potential clinical utility of topical UMEC in subjects with axillary hyperhidrosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.14651","type":"journal-article","created":{"date-parts":[[2017,10,21]],"date-time":"2017-10-21T09:06:37Z","timestamp":1508576797000},"page":"145-151","source":"Crossref","is-referenced-by-count":14,"title":["A phase 2a randomized controlled study to evaluate the pharmacokinetic, safety, tolerability and clinical effect of topically applied Umeclidinium in subjects with primary axillary hyperhidrosis"],"prefix":"10.1111","volume":"32","author":[{"given":"A.","family":"Nasir","sequence":"first","affiliation":[{"name":"Wake Research Institute Raleigh NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Bissonnette","sequence":"additional","affiliation":[{"name":"Innovaderm Research Inc. Montreal QC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Maari","sequence":"additional","affiliation":[{"name":"Innovaderm Research Inc. Montreal QC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"DuBois","sequence":"additional","affiliation":[{"name":"DermResearch Inc. Austin TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Pene Dumitrescu","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Modeling and Simulation GlaxoSmithKline Upper Merion PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Haddad","sequence":"additional","affiliation":[{"name":"Dermatology Therapeutic Area Unit GlaxoSmithKline Collegeville PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Dermatology Therapeutic Area Unit GlaxoSmithKline Collegeville PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Dalessandro","sequence":"additional","affiliation":[{"name":"Dermatology Therapeutic Area Unit GlaxoSmithKline Collegeville PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,11,7]]},"reference":[{"key":"e_1_2_8_2_1","first-page":"285","article-title":"Management of hyperhidrosis","volume":"7","author":"Stashak AB","year":"2014","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(89)70063-3"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2003.12.029"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000000949"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2003.12.040"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.4065\/80.5.657"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2014.06.008"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.02.012"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14081"},{"key":"e_1_2_8_11_1","unstructured":"Stiefel laboratories clinical study report W0266\u201001: a single center randomized double\u2010blind vehicle\u2010controlled proof\u2010of\u2010concept study of glycopyrrolate in the treatment of primary axillary hyperhidrosis. Version 1.0 dated 20\u2010Jan\u20102009 GSK Compound Number BRL\u201029095."},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.2165\/11587870-000000000-00000"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.07884.x"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1159\/000060693"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1971.tb14086.x"},{"key":"e_1_2_8_16_1","first-page":"459","article-title":"Contact sensitization to an antiperspirant with the active ingredient propantheline bromide","volume":"34","author":"Przybilla B","year":"1983","journal-title":"Hautarzt"},{"key":"e_1_2_8_17_1","volume-title":"35th Anniversary Fall Clinical Dermatology Conference","author":"Pariser DM"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13745"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12518"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12406"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.14651","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.14651","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.14651","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.14651","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:57:25Z","timestamp":1791280645000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.14651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,7]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1111\/jdv.14651"],"URL":"https:\/\/doi.org\/10.1111\/jdv.14651","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,7]]}}}